Gilead Sciences (NASDAQ: GILD) had its target price upped by RBC Capital from $44.00 to $50.00 in a report released on Thursday. RBC Capital currently has an outperform rating on the stock.
GILD has been the subject of a number of other recent research reports. Analysts at Credit Suisse reiterated an outperform rating on shares of Gilead Sciences in a research note to investors on Wednesday, February 27th. They now have a $55.00 price target on the stock. Separately, analysts at Bank of America reiterated a buy rating on shares of Gilead Sciences in a research note to investors on Monday, February 25th.
Twenty-one analysts have rated the stock with a buy rating, three have given an overweight rating, and six have assigned a hold rating to the company’s stock. The company presently has a consensus rating of overweight and a consensus price target of $47.50.
Shares of Gilead Sciences opened at 43.45 on Thursday. Gilead Sciences has a 52 week low of $22.40 and a 52 week high of $43.50. The stock’s 50-day moving average is currently $40.50. The company has a market cap of $66.008 billion and a P/E ratio of 26.49.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
